

**WHAT IS CLAIMED IS:**

1. A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a composition that reduces an amount of said bcl-6 protein or of a ribonucleic acid molecule encoding said bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.  
5
2. The method of claim 1, wherein said cell is a lymphoma cell.
3. The method of claim 2, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
4. A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a composition that reduces an amount of said bcl-6 protein or of a ribonucleic acid molecule encoding said bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.  
10
5. The method of claim 4, wherein said lymphoma is a non-Hodgkin's lymphoma.
6. A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a composition comprising a nucleic acid molecule complementary to a region of a ribonucleic acid molecule encoding said bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.  
15
7. The method of claim 6, wherein said cell is a lymphoma cell.

8. The method of claim 7, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
9. The method of claim 6, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.
- 5 10. The method of claim 6, wherein nucleic acid molecule has a sequence selected from the sequences set forth in SEQ ID No: 2, 6, 7, or 10 or a fragment thereof.
11. A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a composition comprising a nucleic acid molecule complementary to a region of a ribonucleic acid molecule 10 encoding said bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.
12. The method of claim 11, wherein said lymphoma is a non-Hodgkin's lymphoma.
13. The method of claim 11, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.
- 15 14. The method of claim 11, wherein nucleic acid molecule has a sequence selected from the sequences set forth in SEQ ID No: 2, 6, 7, or 10 or a fragment thereof.
15. A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a composition comprising a nucleic acid molecule

corresponding to a region of a ribonucleic acid molecule encoding said bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.

16. The method of claim 15, wherein said cell is a lymphoma cell.
17. The method of claim 16, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
18. The method of claim 15, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.
19. The method of claim 15, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.
- 10 20. The method of claim 15, wherein said region has a sequence complementary to the sequences set forth in SEQ ID No: 2, 6, 7, or 10 or a fragment thereof.
- 15 21. A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a composition comprising a nucleic acid molecule corresponding to a region of a ribonucleic acid molecule encoding said bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.
22. The method of claim 21, wherein said lymphoma is a non-Hodgkin's lymphoma.

23. The method of claim 21, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.
24. The method of claim 21, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.
- 5 25. The method of claim 21, wherein said region has a sequence complementary to the sequences set forth in SEQ ID No: 2, 6, 7, or 10 or a fragment thereof.
- 10 26. A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a vector expressing a nucleic acid molecule complementary to a region of a ribonucleic acid molecule encoding said bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.
27. The method of claim 26, wherein said cell is a lymphoma cell.
28. The method of claim 27, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
29. The method of claim 26, wherein said vector is a lentiviral vector.
- 15 30. The method of claim 26, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.
31. The method of claim 26, wherein said nucleic acid molecule has a sequence selected

from the sequences set forth in SEQ ID No: 2, 6, 7, or 10 or a fragment thereof.

32. A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a vector expressing a nucleic acid molecule complementary to a region of a ribonucleic acid molecule encoding said bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.  
5
33. The method of claim 32, wherein said lymphoma is a non-Hodgkin's lymphoma.
34. The method of claim 32, wherein said vector is a lentiviral vector.
35. The method of claim 32, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.  
10
36. The method of claim 32, wherein said nucleic acid molecule has a sequence selected from the sequences set forth in SEQ ID No: 2, 6, 7, or 10 or a fragment thereof.
37. A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a vector expressing a nucleic acid molecule corresponding to a region of a ribonucleic acid molecule encoding said bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.  
15
38. The method of claim 37, wherein said cell is a lymphoma cell.

39. The method of claim 38, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
40. The method of claim 37, wherein said vector is a lentiviral vector.
41. The method of claim 37, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.
42. The method of claim 37, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.
43. The method of claim 45, wherein said region has a sequence complementary to the sequences set forth in SEQ ID No: 2, 6, 7, or 10 or a fragment thereof.
- 10 44. A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a vector expressing a nucleic acid molecule corresponding to a region of a ribonucleic acid molecule encoding said bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.
- 15 45. The method of claim 44, wherein said lymphoma is a non-Hodgkin's lymphoma.
46. The method of claim 44, wherein said vector is a lentiviral vector.
47. The method of claim 44, wherein said nucleic acid molecule is a short interfering

ribonucleic acid (siRNA) molecule.

48. The method of claim 44, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.
49. The method of claim 44, wherein said region has a sequence complementary to the sequences set forth in SEQ ID No: 2, 6, 7, or 10 or a fragment thereof.  
5
50. An isolated nucleic acid molecule having a sequence selected from the sequences set forth in SEQ ID No: 1-10.
51. An oligo-deoxyribonucleic acid (ODN) molecule having a sequence corresponding to the isolated nucleic acid molecule of claim 50 or a fragment thereof, wherein said fragment is about 21-23 nucleotide in length.  
10
52. A composition comprising the isolated nucleic acid molecule of claim 50.
53. A vector comprising the isolated nucleic acid molecule of claim 50.
54. A cell comprising the isolated nucleic acid molecule of claim 50.
55. An isolated nucleic acid molecule having a sequence complementary to a sequence selected from the sequences set forth in SEQ ID No: 1-10.  
15
56. A short interfering ribonucleic acid (siRNA) molecule having a sequence corresponding to a fragment of the isolated nucleic acid molecule of claim 55,

wherein said fragment is about 21-23 nucleotide in length.

57. A short hairpin RNA (shRNA) molecule comprising a sequence corresponding to a fragment of the isolated nucleic acid molecule of claim 55, wherein said fragment is about 19-23 nucleotide in length.
58. A composition comprising the isolated nucleic acid molecule of claim 55.
59. A vector comprising the isolated nucleic acid molecule of claim 55.
60. A cell comprising the isolated nucleic acid molecule of claim 55.